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ABSTRACT Effector binding to liganded hemoglobin (Hb) provides a new understanding of structural determinants of Hb
function. L35, a bezaﬁbrate-related compound, is one of the more potent synthetic regulators of Hb oxygen (O2) afﬁnity. In the
presence of inositol hexaphosphate and bezaﬁbrate (or derivatives), liganded Hb at low pH (pH;6.5) exhibits extremely low O2
afﬁnity and very low cooperativity. In this study, the nature of L35 binding to COHbA at pH 6.35, an altered R-state, is presented.
Solution-active site-speciﬁc spectroscopic probings by front-face ﬂuorescence and circular dichroism reveal that L35 induces
a global heterogeneous conformation in COHbA at pH 6.35 that includes: a T-like structural feature at the a1b2 interface; an
R-like structural feature within the heme environment; and an intermediate-like state at the central cavity. These long-range
structural perturbations appear to stem from L35 binding to two classes of binding sites: the central cavity (primarily at the aa
cleft) and the surface. These results indicate that L35 induces an allosteric transition species, characterized by domain-speciﬁc
tertiary and quaternary-like conformation within a global R-quaternary structure.
INTRODUCTION
It has been believed that allosteric effectors function by
binding to deoxy hemoglobin (Hb). However, recent studies
demonstrate binding of allosteric effectors to liganded Hb,
contributing a new understanding of the allosteric transition
and structural determinants regulating Hb function. In the
absence of heterotropic effectors, stripped Hb is a high-
afﬁnity, moderately cooperative oxygen carrier, exhibiting
a Bohr effect, with limited functional diversity. In the
presence of heterotropic effectors, Hb exhibits signiﬁcant
functional diversities; and, in vivo, endogenous red blood
cell heterotropic effectors modulate Hb function in ways
critical to its efﬁcacy as an oxygen carrier (Hirsch et al.,
1999; Yonetani et al., 2002; Chen et al., 2002). Such
functional diversities are generated primarily through tertiary
conformational constraints caused by effector interaction
with Hb, especially oxyHb (Yonetani et al., 2002). These
studies have led to the proposal that the classic deﬁnition of
the quaternary R and T structure by Perutz (1970) is only
relevant to Hb stripped of organic phosphates and other
natural regulators.
Bezaﬁbrate (BZF) derivatives, potent heterotropic alloste-
ric effectors of Hb, are useful tools to probe Hb structure and
function. These compounds exhibit anti-gelling and antihy-
perlipoproteinemic properties, and bind reversibly to intra-
erythrocytic Hb, decreasing O2 afﬁnity (Poyart et al., 1994).
The early application of BZF derivatives to Hb research and
therapeutics was based on the assumption that the drug
interacts only with T-state Hb (Murray et al., 1988a,b; Noble
et al., 1989; Bettati et al., 1997). However, this assumption
was negated by several solution and crystal studies de-
monstrating that BZF and its derivatives interact with R-state
Hb at neutral pH and modulate Hb function (Marden et al.,
1988, 1990; Coletta et al., 1995, 1999; Shibayama et al.,
2002).
Laser photolysis studies of COHbA show that BZF
decreases the CO association rate of R-state Hb by over
a factor of 4 (Marden et al., 1988, 1990). The O2 dissociation
rate constant (measured by CO displacement of fully
liganded oxyHbA) plotted as a function of BZF concentra-
tion results in BZF-saturable binding site(s), indicating that
oxyHbA interacts with BZF (Coletta et al., 1999). The
addition of BZF to stripped oxyHb dramatically decreases
O2 afﬁnity in the absence of cooperativity, and enhances the
Bohr effect—all indicative of BZF binding to R-state Hb
(Tsuneshige et al., 2002). A recent high-resolution crystal
structure of carbonmonoxy-Hb-BZF complex, obtained in
low-ionic strength polyethylene-glycol medium at pH 6.8
acetate ammonium (50 mM), revealed a new allosteric
binding site of BZF to R-state Hb located near the surface of
the E-helix of each a-subunit. The complex maintains the
R-state quaternary structure (Shibayama et al., 2002).
Liganded Hb at low pH (pH ;6.5), in the presence of
allosteric effectors (e.g., inositol hexaphosphate, i.e., IHP,
and BZF), has been used to explore effector binding given its
low O2 afﬁnity and low cooperativity (Lalezari et al., 1990;
Yonetani et al., 2002; Tsuneshige et al., 2002). However,
liganded Hb in the presence of heterotropic effectors
generates a variety of structural interpretations: 1), ‘‘liganded
T-state with partially oxygenated Hb tetramer constrained in
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the T-state’’ (Lalezari et al., 1990; Marden et al., 1988,
1990); 2), ‘‘liganded R-state with tertiary structural con-
straints’’ (Yonetani et al., 2002); and 3), ‘‘a special state that
stabilizes a tertiary T-like conformation within a quaternary
R-like intermediate structure’’ (Coletta et al., 1999).
Speciﬁcally, COHbA at pH 6.35, originally deﬁned in the
presence of organic phosphate as ‘‘an altered R-state Hb’’ by
Scott et al. (1983), has recently been classiﬁed as ‘‘a
snapshot of an R-T intermediate in the presence of inorganic
phosphate’’ (Safo et al., 2002). Moreover, COHbA at pH
6.35 forms crystal structure intermediates R3 and RR2
(between R and R2) (Safo and Abraham, 2003).
In the present study, we aim to clarify the various structural
interpretations by spectroscopically exploring the binding
properties of L35, aBZF derivative (Poyart et al., 1994), to the
low pH altered R-state, correlated with site-speciﬁc structural
changes in both heme and globin domains (Scott et al., 1985).
The altered R-state has proven useful in solution studies
probing central cavity differences in variant hemoglobins and
in comparative effector binding studies (e.g., Hirsch et al.,
1996, 1997, 1999; Chen et al., 2002; Fablet et al., 2003).
Using the low pH transition state, evidence is presented that
shows L35 induces a transition species characterized by
domain-speciﬁc tertiary and quaternary-like conformation
within a global R-quaternary structure.
EXPERIMENTAL PROCEDURES
Materials
L35 (Fig. 1) was synthesized and prepared as used before (Lalezari et al.,
1990). A stock solution was prepared by dissolving in distilled water with
the addition of NaOH and titrated to the desired pH. The sodium salt of
inositol hexaphosphate (IHP) was prepared as described (Chen et al., 2002).
A stock solution of 8-hydroxy-l, 3, 6-pyrenetrisulfonate (HPT) was prepared
in 0.05 M HEPES, pH 6.35.
Hemoglobin puriﬁcation
HEPES buffer has been employed to preserve the integral nature of stripped
hemoglobins that could be compromised when using a phosphate buffer
(Hirsch et al., 1996, 1999). The advantages of HEPES buffer are reviewed at
length by Yonetani et al. (2002).
HbA was puriﬁed from AA hemolysates followed by DE-52 anion
exchange chromatography as routinely performed in our lab (e.g., Hirsch
et al., 1999; Chen et al., 2002). COHbA was prepared by gently passing
chemically pure CO gas over the surface of the Hb solution, and then dialyzed
overnight against 0.05 M HEPES, pH 6.35. All observations employed Hb
concentrations wherein the Hb tetramer predominates (Hirsch, 1994).
Hemoglobin labeling
Binding of iodoacetamidoﬂuorescein (5-IAF) to b93Cys was carried out as
previously described (Chen et al., 2002). The purity of the Hb-AF conjugate
was veriﬁed by observation of a single band on isoelectric focusing gel and
a single modiﬁed b-chain peak (a mass of 16,253 compared to the normal
b-chain mass of 15,867) by mass spectrometry.
Steady-state front-face ﬂuorescence
spectroscopy
Steady-state front-face ﬂuorescence spectroscopy was performed with
a SLM 8000 photon-counting spectrophotometer (SLM-Aminco, Foster
City, CA) equipped with a front-face cuvette holder. A concentration of
1.0 g % COHb was used, a condition where the tetramer predominates.
Front-face ﬂuorescence is an established technique to determine the
intrinsic ﬂuorescence of Hb and extrinsic ﬂuorophores bound to Hb (for a
review of Hb front-face ﬂuorometry, see Hirsch, 1994, 2000, 2003).
Circular dichroism spectroscopy
Circular dichroism spectra of COHbA in the presence and absence of
allosteric effectors were recorded on a JASCO- J720 spectropolarimeter
(JASCO, Tokyo, Japan) with a 0.05-cm cell-length cuvette (125 ml). A
COHb concentration of 0.7 g % (0.11 mM) Hb tetramer was used. All
circular dichroism (CD) measurements were performed at room temperature
of 22C with molar ellipticity in terms of Hb tetramer.
Surface plasmon resonance (SPR)
BIAcore-3000 (Biacore, Neuchaˆtel, Switzerland), a SPR-based biosensor,
was used to determine the binding constant of L35 to COHbA. COHbA at
a concentration of 0.65 g % (0.1 mM Hb tetramer) was immobilized to the
carboxymethylated dextran layer of a CM5 biosensor chip (Biacore) via
amine covalent coupling. Immobilization was carried out in HEPES buffer
(50 mM, pH 6.35) at a ﬂow rate of 100 ml/min. The ﬂow-cell surface was
activated by a mixture of n-hydroxysuccinimide (NHS) and n-ethyl-n9-
(dimethyl-aminopropyl)-carbodiimide (EDC). An immobilization level of
4500–7500 resonance units was obtained. A nonderivatized ﬂowcell serves
as a reference surface.
L35 binding to COHbA immobilized on the biosensor chip was
conducted at a ﬂow rate of 100 ml/min. A 5-mM L35 stock solution was
prepared directly in the running buffer (50 mM HEPES, pH 6.35) from
which a serial twofold dilution (each in duplicate aliquots) was made and
injected. To ensure complete dissociation of L35 from COHbA, a 50-mM
glycine-NaOH buffer (pH 8.5) was used to regenerate the sensor surface
after each L35 injection.
RESULTS
L35 binding alters the Hb intrinsic ﬂuorescence
reﬂective of a1b2 interface
conformational changes
Long-range site-speciﬁc intramolecular conformational per-
turbations by ligand binding may be probed in solution by
a variety of spectroscopic techniques that focus on speciﬁc
molecular domains. This complements crystallography by
providing access to conformational changes that may be
restricted by the crystal lattice. Front-face ﬂuorescence is
useful for probing conformational differences of mutantFIGURE 1 The chemical structure of L35 (Lalezari et al., 1990).
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hemoglobins in the microdomains of the central cavity and
the a1b2 interface (Hirsch et al., 1996, 1999). Hb intrinsic
ﬂuorescence is primarily due to the ﬂuorescence of b37Trp
at the a1b2 interface, though it may contain some con-
tribution by the surface Trp residues, a14 and b15Trps
(Hirsch 1994, 2000, 2003). Furthermore, Hb intrinsic ﬂuores-
cence serves as a reporter for quaternary transition (Hirsch
et al, 1980; Hirsch and Nagel, 1981). The CO-liganded form
of Hb exhibits an intrinsic ﬂuorescence emission maximum
at 322 nm. Compared to the CO-liganded form, deoxyHb
exhibits increased ﬂuorescence intensity, concomitant with
a red shift of the emissionmaximum to 325 nm. (Although the
exact wavelength may deviate by a few nanometers de-
pendent on the spectrophotometer, the relative changes are
maintained.)
Titration of COHbA with L35 causes a red shift in the
emission maximum wavelength (to ;329 nm) and a pro-
gressive decrease in the intensity of the intrinsic ﬂuorescence
of COHbA at pH 6.35 (Fig. 2 A). A shift of the intrinsic
ﬂuorescence emission of Hb to longer wavelengths indicates
that Trp residues become more exposed upon L35 binding.
The intrinsic ﬂuorescence intensity changes as a function of
L35 concentration generate titration curves that appear to be
biphasic (Fig. 2 B). Three to ﬁve independent measurements
were obtained for each data point on the curves. Given the
excellent reproducibility of each point as shown by the
standard deviations (see error bars, Fig. 2 B), the breaks in
the curves (i.e., abrupt change of slope), although small,
appear real and should not be ignored. Hence, two relatively
weak binding sites are suggested (mM KD values, Table 1).
Further support for the biphasic nature of the curves stems
from the following. The KD of the second weaker binding
site (KD2), obtained from ﬂuorescence data, is consistent
with the KD derived from the surface plasmon resonance
study (presented below). Furthermore, as elaborated in the
discussion, the suggestion of two binding sites best explains
the L35-induced conformational changes probed by other
spectroscopic techniques (e.g., changes in extrinsic ﬂuores-
cence of Hb-bound HPT and the perturbations of the CD
spectra shown below). Moreover, it is not unusual for
allosteric effectors to exhibit low binding afﬁnities to
liganded Hb. For example, IHP binds to COHb (pH 7.0) at
two sites (KD1 ¼ 0.40 mM; KD2 ¼ 6.3 mM, Coletta et al.,
1993). BZF binds to liganded Hb, with a KD of 15 or 40 mM,
dependent upon the heme ligand, solution conditions, and
assay techniques (Ascenzi et al., 1993; Coletta et al., 1999).
L35 titration of Hb, in the presence of IHP, results in
a greater intrinsic ﬂuorescence intensity decrease than with
L35 alone. The enhancement of L35 binding by IHP is seen
by a 44% increase in the L35 binding afﬁnity for the higher
afﬁnity binding site, and a 10% increase for the lower afﬁnity
binding site (Table 1). In contrast, chloride inhibits the effect
of L35 on intrinsic ﬂuorescence changes: L35 titration of Hb
in the presence of Cl alone or Cl with IHP minimizes the
L35 effect as seen by a 6–22% decrease in the two binding
afﬁnities of L35 (Table 1). The opposing coupling effects of
L35 and IHP compared to L35 and Cl proves signiﬁcant
since titration of COHbA at pH 6.35 with either IHP or
chloride (Cl) alone insigniﬁcantly alters the intrinsic ﬂuo-
rescence of the altered R-state Hb. Notably, in the presence
of Cl, the IHP enhancement of L35 binding becomes null,
as reﬂected in the similar KD (Table 1).
L35 affects the central cavity as seen by the
extrinsic ﬂuorescence of HPT-bound COHbA
HPT is an established ﬂuorescent 2,3-bisphosphoglycerate
(BPG) analog with an emission maximum (em. max. 385 nm
FIGURE 2 Intrinsic ﬂuorescence emission spectra of COHbA as a func-
tion of L35 concentration (A) and L35 titration of COHbA as a function
of intrinsic ﬂuorescence intensity changes (B). Fluorescence excitation at
280 nm. (0.05 M HEPES, pH 6.35, 1.0 g % COHbA, 25C.) Titration curves
for COHbA alone and COHbA1IHP were obtained from the average
of three reproducible titrations. Titration curves for COHbA1Cl and
COHbA1Cl1IHP were obtained from the average of ﬁve reproducible
titrations (see error bar #1%). Note that the symbols for COHbA1Cl (=)
and COHbA1Cl1IHP (;) overlap in a nearly identical fashion. The
derived KD values are shown in Table 1.
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when excited at 280 nm) different from that of the intrinsic
Hb ﬂuorescence (em. max. 330 nm) (MacQuarrie and
Gibson, 1971, 1972; Gottfried et al., 1997). It has been
established that HPT binds to the b–b cleft of the central
cavity of deoxy Hb at the BPG binding pocket (MacQuarrie
and Gibson, 1971, 1972; Serbanescu et al., 1998). When
bound to Hb, HPT ﬂuorescence is quenched by the heme
and results in signiﬁcantly reduced ﬂuorescence. Front-face
optics is advantageous in that it permits a direct observation
of HPT ﬂuorescence in the presence of Hb (for a review, see
Hirsch, 2000, 2003). Several central cavity-binding effec-
tors, such as IHP and Cl, displace HPT from the central
cavity of the altered R-state Hb as indicated by an intensity
increase in HPT ﬂuorescence (Hirsch et al., 1999; Chen et al.,
2002; Fablet et al., 2003).
L35 titration to Hb-bound HPT results in an increased
HPT ﬂuorescence intensity, indicating its release from the
central cavity (Fig. 3 A). In contrast, titrating L35 into a Hb-
free HPT solution results in quenching of HPT ﬂuorescence
by L35. In the presence of IHP, the ﬂuorescence of HPT is
greater than in the absence of IHP (Fig. 3 B), since
a signiﬁcant amount of HPT has already been displaced
from the central cavity by IHP. L35 titration into a mixture of
IHP and HPT-bound Hb leads to a further increase in the
HPT ﬂuorescence (Fig. 3 B), indicating more HPT released
from the central cavity. The synergistic effect of IHP on L35
displacement of HPT is consistent with 1), the observed IHP
effect on L35 quenching of the intrinsic ﬂuorescence of
COHb (Fig. 2 B); and 2), the known synergistic action of
L35 and IHP in decreasing the Hb O2 afﬁnity (Lalezari et al.,
1990).
In contrast, L35 titration of HPT–bound Hb in the
presence of Cl results in decreasing HPT ﬂuorescence
(Fig. 3 B). Compared to IHP, a greater amount of HPT is
displaced out of the central cavity by Cl before L35
titration. A decreasing HPT ﬂuorescence indicates that some
HPT rebinds to the central cavity. In the presence of both Cl
and IHP, the IHP and L35 synergistic effect is not present.
Indeed, the overall effect of the Cl and IHP combination, on
L35 displacement of HPT, is almost identical to that when
Cl alone is present before L35 titration (Fig. 3 B). This is in
agreement with the loss of the synergistic effect of IHP on
L35 intrinsic ﬂuorescence quenching seen in the presence of
Cl (Table 1). The competitive effect of Cl and L35 on
HPT displacement and on the intrinsic ﬂuorescence quench-
ing is consistent with earlier reports that Cl and L35 act
competitively to decrease Hb O2 afﬁnity (Lalezari et al.,
1990; Yonetani et al., 2002).
L35 binding perturbs b93Cys as reﬂected in the
COHbA-AF extrinsic ﬂuorescence changes
b93Cys is located in a conformationally ﬂexible domain
containing residues whose interactions are directly linked to
allosteric properties of the Hb tetramer (Perutz, 1970, 1990;
Perutz et al., 1998; Khan et al., 2001). The reactivity of
b93Cys is a function of both the quaternary and tertiary
structures of HbA (Riggs, 1952, 1961; Riggs and Wolbach,
TABLE 1 Binding afﬁnities of L35 to COHbA in the presence/
absence of other allosteric effectors as determined by changes
in the intrinsic ﬂuorescence of Hb
Effectors KD1 (mM) KD2 (mM) R
2
L35 0.41 0.94 0.998
L351IHP 0.23 0.85 0.999
L351Cl 0.50 1.00 0.998
L L351Cl1IHP 0.47 1.02 0.998
Conditions: 1.0 g % COHbA, 50 mM HEPES, pH 6.35. The KD values and
correlation coefﬁcients (R2) are calculated from curve-ﬁtting analysis using
Sigma Plot.
FIGURE 3 Extrinsic ﬂuorescence emission spectra of COHbA-bound
HPT as a function of L35 concentration (A) and L35 titration of Hb-bound
HPT in the absence/presence of IHP and Cl (B). Fluorescence excitation at
280 nm, emission at 385 nm. (0.05 M HEPES, pH 6.35, 1.0 g % COHbA,
0.31 mM IHP, 0.1 M Cl, 25C.)
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1956; Vasquez et al., 1999). The Cys side chain is exposed to
solvents in liganded HbA (accessible to thiol reagents for
b93 modiﬁcations), but buried in the unliganded T-state
(non-accessible to thiol reagent modiﬁcations). The ﬂuores-
cent probe, IAF, covalently bound to oxyHbA, reports b93
local environmental changes close to the heme. In the oxy
state, the probe is in a particularly hydrophilic environment
and becomes less exposed upon deoxygenation (Hirsch et al.,
1986). IAF modiﬁcation of HbA results in a greatly
increased oxygen afﬁnity and decreased cooperativity, which
constitutes the most extreme functional alteration yet re-
ported for thiol reagent modiﬁcations (Chen et al., 2002).
A decreased ﬂuorescein ﬂuorescence intensity is observed
upon L35 titration (Fig. 4). The titration curve, plotted as the
percent decrease in ﬂuorescein ﬂuorescence intensity versus
L35 concentration, exhibits a sigmoid shape. A KD of
0.48mMwas obtained from the midpoint of the curve (Fig. 4,
inset). The decrease in ﬂuorescein ﬂuorescence intensity may
be explained by: 1), a more exposed b93Cys side chain as
a function of L35 binding; or more simply, 2), L35 directly
quenches ﬂuorescein ﬂuorescence. Since the altered R-state
b93Cys side chain of COHbA appears to be less exposed
than in liganded Hb at pH 7.35 (R-state) R. E. Hirsch,
unpublished data), it is likely that L35 binding results in
further exposure of the b93Cys side chain (toward a more R-
like state), reﬂected in the observed decreased ﬂuorescence.
This is consistent with an L35-induced R-like heme
environment supported by the CD data shown below.
The possibility of ﬂuorescence energy transfer from
ﬂuorescein to L35, within the range of excitation (480
nm), is improbable since the L35 absorption spectrum does
not overlap with either the ﬂuorescein excitation (absorption)
or emission spectra. Furthermore, both static and dynamic
quenching would require contact of the quencher with the
ﬂuorophore within the solvent shell (Lakowicz, 1999).
However, there is no evidence to date that L35 or similar
compounds bind at or near the b-chain heme domain.
Speciﬁc binding of L35 to sensorchip-immobilized
COHbA as detected by surface
plasmon resonance
Surface plasmon resonance (SPR)-based biosensors, such as
BIAcore, are used to determine binding constants for
macromolecular interactions (Myszka, 1997; Myszka et al.,
1999; Rich and Myszka, 2000; Day et al., 2002).
Immobilization of Hb to the CM5 sensorchip surface uses
primary amines (the N-terminal amines and surface lysines)
for covalent coupling. Therefore, this Hb immobilization
should restrict access to the N-terminal b1Val (which lies at
the entrance of the central cavity bb cleft), and a1Val
(located in the entrance of the aa cleft). We demonstrate
here that the central cavity entrance is blocked using SPR
methodology: the N-terminal amino acids are covalently
bound to the carboxymethylated dextran layer of the
sensorchip surface, imposing steric hindrance for the ac-
cessible of effectors such as IHP and Cl. This becomes
advantageous by serving as a control to test the proposed
L35 binding site(s) indicated by the ﬂuorescence results.
The observations support the prediction of a blocked Hb
central cavity entrance both at the aa and bb clefts when
COHbA is immobilized to the sensorchip surface, since,
uncharacteristically, IHP and Cl show no binding to
hemoglobin (Fig. 5, A and B insets). L35 only shows
a low-afﬁnity binding, equivalent to the secondary binding
site as identiﬁed by the intrinsic ﬂuorescence titration (Fig. 5
A). Also, Cl or IHP has no effect on L35 binding to the
sensor surface (Fig. 5 B). These various controls are con-
sistent with a model that L35 binds to a low-afﬁnity noncen-
tral cavity-binding site, most likely the secondary binding
site indicated by intrinsic ﬂuorescence (Fig. 2).
The surface plasmon resonance response of the L35
interaction with COHbA is that of a complete binding cycle,
achieving the expected association plateau and subsequent
dissociation toward the baseline (Fig. 5, A and B). A rapid
downfall of the dissociation curve provides further evidence
that this is not a high-afﬁnity binding. Plotting the maximum
resonance response as a function of L35 concentration
generates a sigmoid binding curve (Fig. 5 C). The
dissociation constant (KD ¼ 1.5 mM) of L35 binding to
COHbA can be derived from the midpoint value of the curve
(Fig. 5 C). The KD determined from the biosensor is
comparable to the secondary L35 binding obtained by the
solution-based front-face ﬂorescence data (Table 1, KD2 ¼
0.94 mM), with the small difference in KD attributed to the
difference in methods. Moreover, a control study employing
COHbA-AF immobilized onto the sensorchip surface shows
that L35 exhibits a signiﬁcantly weakened noncentral cavity
binding to COHbA-AF compared to unmodiﬁed COHbA
(KD ¼ 10 mM as derived from the midpoint of the binding
FIGURE 4 Extrinsic ﬂuorescence emission spectra of b93 ﬂuorescein
(IAF) modiﬁed COHbA (COHbA-AF) as a function of L35 concentration.
(Inset) L35 titration of COHbA-AF. Fluorescence excitation at 480 nm,
emission at 520 nm. (0.05 M HEPES, pH 6.35, 1.0 g % COHbA-AF, 25C.)
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curve; Fig. 5 C, inset). This low-afﬁnity binding is too
weak (a KD of 10 mM) to be reﬂected in the L35 titration
range (0–1.5 mM) of the COHbA-AF monitored by
ﬂuorescein ﬂuorescence (Fig. 4). Thus, the L35 titration of
COHbA-AF results in a sigmoid-shape titration curve (Fig.
4), implying a low-afﬁnity L35 binding site with aKD of 0.48
mM. In contrast, L35 titration of unbound COHbA
(monitored in solution by the intrinsic ﬂuorescence) results
in the appearance of a biphasic-like curve, indicating two
classes of binding afﬁnities (Fig. 2 B).
L35 effect on COHbA conformation at the heme
and a1b2 interface as probed by CD
CD spectra in the near-UV region (250–300 nm) arise from
tryptophanyl, tyrosyl, and phenylalanyl residues, the S-S
bridge, and the heme groups (Timasheff, 1970). CD bands at
;260 nm stem from the phenylalanyl residues. They are the
least sensitive to alterations in their environment but are very
responsive to the state of the heme (Simon and Cantor,
1969). Speciﬁcally, the 270–290 nm region CD band
provides a sensitive probe for human Hb quaternary structure
at the a1b2 interface (Perutz et al., 1974a,b,c; Perutz, 1976).
The 280–290 nm CD bands reﬂect the local environments of
b37Trp, a42Tyr, a140Tyr, and b145Tyr (Plese and Amma,
1977; Plese et al., 1977; Baldwin and Chothia, 1979;
Abraham et al., 1991; Li et al., 2000a,b), which are located at
the a1b2 interface. The sharp negative trough in the CD
spectrum at ;280–290 nm is characteristic of the globin
quaternary structural changes, but independent of the state of
ligation of the heme and the accompanying changes in globin
chain tertiary structure (Perutz et al., 1974a,b,c). However,
the relative contributions of these residues to the 280-nm
region UV CD changes have not been assigned (Li et al.,
2000a,b).
The CD spectra of COHbA (stripped 50 mM HEPES at
pH 6.35) in the near-UV and Soret regions in the absence and
presence of L35 are shown in Figs. 6–7. (For a comparison,
the effect of other allosteric effectors such as IHP and Cl on
the CD spectra of COHbA is also presented; see Figs. 6–7,
insets.) IHP and Cl alone do not exhibit CD bands in the
spectral region 250–650 nm. L35 has a weak CD band at 259
nm, which may interfere with the much stronger Hb CD band
in the 260-nm region. However, there is no interference with
the Hb 280-nm region CD band.
Notably, L35 induces a deep negative trough at;280 nm in
COHbA, indicative of a T-like quaternary structure feature at
thea1b2 interface (Perutz et al., 1974a,b,c). This is consistent
with the observed L35-induced red-shift in intrinsic ﬂuo-
rescence emissions, a T-like feature, since the emission
maximum of the intrinsic ﬂuorescence of deoxyHbA red-
shifts to 325 nm compared toCOHbA at pH 7.35 in phosphate
buffer (321 nm) (Hirsch and Nagel, 1981). However, the
simultaneous presence of L35 and IHP results in a complete
loss of the negative trough at 280 nm, whereas the presence of
L35 and Cl together induces only a diminished negative
trough (Fig. 6). A complete loss of the negative trough at 280
nm occurs with the simultaneous presence of L35, IHP, and
FIGURE 5 Surface plasmon resonance raw sensorgrams and binding
curves for the interaction of sensorchip-immobilized COHbA with effectors.
(Conditions: 0.65 g% COHbA or COHbA-AF, 50 mM HEPES, pH 6.35.)
(A) Titration of L35 alone; (B) L351IHP and L351Cl. (Conditions: 1.0 mM
IHP; 0.1 M Cl.) The binding curves of L35 alone (triangle and solid line),
L35 1 IHP (circle and dashed line), and L351chloride (square and dotted
line), plotted by taking the plateau value as a function of L35 concentration
are shown in C. (Inset) A comparison of L35 binding curves for COHbA and
COHbA-AF. The points on the curve represent the highest resonance units
(plateau value) for the respective effector(s) concentration.
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Cl, similar to the absence of the negative trough observed
in the COHbA-L35-IHP complex (Fig. 6).
To ensure that the L35-induced COHbA UV CD changes
are a quaternary conformational event, two different
liganded Hb controls were performed. COHbA-AF was
chosen as a control since AF modiﬁcation of COHbA at the
b93Cys stabilizes the R-state (Riggs and Wolbach, 1956;
Hirsch et al., 1986). The second control employs COHbA at
pH 7.35. In the presence of L35, the negative trough within
the 280-nm region is not observed for COHbA-AF and for
COHbA at pH 7.35 (data not shown).
The Hb Soret region CD bands (410–430 nm) stem from
the p/ p* transition of the heme. Studies show that the CD
bands in the Soret region, as well as in the 500–600-nm
range, are sensitive to the oxidation state of the heme, ligand
speciﬁcity, and subunit interactions (Goodall and Shooter,
1969; Nagai et al., 1969; Geraci and Parkhurst, 1981).
Liganded Hb has a characteristic CD band at ;420 nm
(COHb at 422 nm, oxyHb at 419 nm), which is distinct from
that of deoxy Hb (431 nm) and met Hb (410 nm). Upon L35
binding, both an increase and a merely detectable red-shift in
the ellipticity of COHbA at 422 nm are observed, concurrent
with an increased shoulder at ;407 nm (Fig. 7). The L35-
induced 422-nm region ellipticity increase resembles the
BPG-induced ellipticity increase at 420 nm reported for
oxyHb and deoxy Hb (Sugita et al., 1971). The 407-nm
shoulder is similar to that seen in the COHbA Soret CD
spectrum in the presence of IHP (Fig. 7, inset) as reported by
others (Bucci et al., 1978).
In the absence of L35, Cl alone results in an ellipticity
increase at ;422 nm and a slight shift of the 422-nm CD
band to a shorter wavelength. In the presence of L35, Cl
signiﬁcantly diminishes the L35 effect, whereas IHP
enhances the L35-induced perturbation in the Soret region,
further shifting the 422-nm CD band to a longer wavelength
(Fig. 7). In the presence of both IHP and Cl, there is an
alteration of the L35-induced perturbation that appears as a
small but signiﬁcant shift of the CD band to longer wave-
lengths toward the T-state, but within the R-state assign-
ments. All these results are in agreement with the reported
heterotropic effector-induced tertiary structural changes in
the heme environment (Yonetani et al., 2002; Scott et al.,
1983, 1985), which will be further discussed in this article.
DISCUSSION
Effector binding to liganded Hb provides insight into Hb
allosteric transition. Compared to organic and inorganic
phosphate-induced tertiary structural changes (Scott et al.,
1983, 1985; Safo et al., 2002), L35 induces a global
heterogeneous conformation in COHbA at pH 6.35: a T-like
structural feature at the a1b2 interface, R-like structural
features within the heme environment, and an intermediate-
like state at the central cavity. Therefore, L35 may induce
a transition species characterized by the domain-speciﬁc
tertiary and quaternary-like conformation within a global
R-quaternary structure.
The unique L35-induced structural perturbation stems
from a speciﬁc binding of L35 to COHbA, as indicated by:
1), saturable titration curves (Figs. 2–5); and 2), solution-
and surface-based KD determinations that, taken together,
suggest two classes of binding sites. Although L35 binding
releases Hb-bound HPT, the synergistic effect of L35 and
IHP on HPT displacement (Fig. 3) may indicate that L35
does not bind speciﬁcally at the bb cleft BPG pocket.
Considering that the Cl-binding channel runs through the
central cavity (Ueno and Manning, 1992), the competitive
effect of Cl alone or Cl and IHP on L35 displacement of
FIGURE 6 Near UV region CD spectra of COHbA in the presence of L35
and other effectors: COHbA alone, COHbA1L35, COHbA1L351IHP,
COHbA1L351Cl, and COHbA1L351IHP 1Cl. (Inset) CD spectra of
COHbA alone, COHbA1IHP, and COHbA1Cl. (0.05 M HEPES, pH
6.35, 0.65 g % COHbA, 0.7 mM L35, 0.7 mM IHP, 70 mM Cl, 23C.)
FIGURE 7 Soret region CD spectra of COHbA in the presence of L35 and
other effectors: COHbA alone, COHbA1L35, COHbA1L351IHP,
COHbA1L351Cl, and COHbA1L351IHP1Cl. (Inset) CD spectra of
COHbA alone, COHbA1IHP, and COHbA1Cl. (0.05 M HEPES, pH
6.35, 0.65 g % COHbA, 0.7 mM L35, 0.7 mM IHP, 70 mM Cl, 23C.)
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HPT (Fig. 3) further suggests that L35 binding sites lie
within the central cavity, but not at the BPG site. In
deoxyHb, L35 binds at the interface of the a- and b-subunits
deep in the waterﬁlled central cavity at a distance from the
heme and the organic phosphate binding sites (Lalezari et al.,
1990; Poyart et al., 1994). It is possible that L35 binds deeply
in the central cavity of COHbA and causes a conformational
perturbation transmitted to the bb cleft BPG site, weakening
HPT binding. This possibility is supported by our SPR data
(Fig. 5), wherein immobilization of COHbA (effecting
a blocked central cavity bb cleft entrance) results in only one
low-afﬁnity noncentral cavity binding site, correlated with
the secondary binding site detected by intrinsic ﬂuorescence
(Fig. 2 B). Based upon a recent crystallization study at pH
6.8, showing speciﬁc binding of BZF to horse COHb surface
(i.e., the surface of each a-subunit E-helix) (Shibayama et al.,
2002), it is likely that the secondary binding site of L35 also
resides on the surface, since both L35 and BZF have
chlorobenzene and methyl groups that hydrophobically
interact with the Hb hydrophobic pocket between the E-helix
and the a-chain heme edge. Therefore, for COHbA at low
pH, an altered R-state, L35 may have two classes of binding
sites, one in the central cavity and the other on the Hb sur-
face, resembling binding characteristics intermediate to both
that of the deoxy and CO forms of Hb.
The mixed binding characteristic of L35 mentioned above
may be due to the fact that we are studying an R-like
intermediate (COHb at low pH). A similar notion has been
presented by Safo et al. (2002), showing that COHbA in
phosphate buffer at pH 6.4 may be ‘‘a snapshot of an
intermediate’’ in the allosteric transition. This could be
explained by the L35-induced domain-speciﬁc heteroge-
neous conformational changes reported by spectroscopic
probing. In contrast to the T-like structural feature at the
a1b2 interface, the heme is essentially in an R-state
conformation, even though L35 induces a modest red-shift
CD band in the Soret region. This is further supported by 1),
the L35 induction of an R-like b93Cys microenvironment
seen in COHbA-AF (Fig. 4); and 2), previous reports
demonstrating heterotropic effector-induced tertiary R-state
structural changes in the heme environment (Scott et al.,
1983, 1985; Yonetani et al., 2002).
The issue of domain-dependent R- and T-like structural
features raises a question: how does L35 induce a T-like
structural feature at the a1b2 interface, but not in the heme
environment? Similar domain-dependent R- and T-like
structural features have been previously reported. UV CD
spectra of metal hybrid Hb, such as aFe/Zn bCO, aCO
bFe/Zn, and aFe/Zn bFe/Zn, show a signiﬁcant negative
ellipticity band centered at 280 nm, analogous to T-state Hb
(Fiechtner et al., 1980; Simolo et al., 1986), whereas other
regions, such as Val (E11) and Asp (b89)-Tyr (a42), probed
by NMR resonance and exchangeable proton, resemble the
oxy R structure (Simolo et al., 1986). Additionally, studying
the allosteric effector-induced changes of oxyHbA at the
near-UV and Soret region CD spectra changes, Coletta et al.
(1999) showed that the a1b2 interface of oxyHbA in the
simultaneous presence of IHP and BZF mostly maintains
a quaternary R-tetrameric structure, whereas the heme
conformation conforms to that typical of the low-afﬁnity
structure at neutral pH. They demonstrated that IHP and BZF
together induce a stabilization of a tertiary T-like conforma-
tion within a quaternary R-like structure (Coletta et al.,
1999). Consistent with this ﬁnding is that the stepwise
progress of the Hb allosteric pathway starts with a rearrange-
ment of the contacts at the hinge region and ends with
a rearrangement involving the switch region of the interface
(Goldbeck et al., 2002). Therefore, the L35 structural
perturbation unique to COHbA at low pH may be explained
by the kinetic data of Goldbeck et al. (2002), demonstrating
that b37Trp at the a1b2 interface is the obligatory
conformational change that gives rise to an intermediate
conformer in sequence to the quaternary transition. It is
possible that L35 induces an intermediate conformation
wherein the quaternary structural changes in the hinge region
are not fully transmitted to the switch region of the a1b2
interface and the heme environment.
Based upon the low pH COHbA crystal structure (Safo
et al., 2002), we propose a model of L35-induced intra-
molecular communication pathways, to explain some of the
L35-induced domain-speciﬁc perturbations reported by these
spectroscopic probings. Since L35 binds to different sites
than IHP, and competes with Cl, possible L35 binding
contacts are the a141Arg and a126Asn at the aa cleft, the
well-known Cl binding sites. This serves as the basis for the
proposed communication pathways shown in Scheme I–
Scheme III. Hence, L35 binding at a141Arg could perturb
the a140Tyr and b37Trp in the hinge region of the a1b2
SCHEME I L35-induced intramolecular communication pathway to the
a140Tyr at the hinge region of the a1b2 interface. Asterisk (*) indicates
residues forming side-chain contacts based on PDB1ljw (Safo et al., 2002).
SCHEME II L35-induced intramolecular communication pathway to the
b37Trp at hinge region of the a1b2 interface. See Scheme I for notes.
SCHEME III L35-induced intramolecular communication pathway to the
a87His at the a-heme environment. See Scheme I for notes.
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interface and the a-heme proximal Histidine a87His,
consistent with the ﬂuorescence and CD data. In addition,
L35 binding may invoke other long-range effects on a42Tyr
and b145Tyr, located in the switch region of the interface.
The L35-induced domain-speciﬁc heterogeneous confor-
mational changes are differentially affected by IHP and Cl.
This is summarized in Table 2, showing the effect of IHP and
Cl on L35-induced perturbations in selected domains, as
reported by ﬂuorescence and CD probings. Cl weakens
whereas IHP enhances the L35-induced conformational
perturbations in the central cavity and the heme environment,
suggesting long-range intramolecular communication path-
ways from the central cavity to the heme environment. These
observations underlie the importance of coupled interactions
among effectors and their corresponding central cavity
domains in modulating Hb conformation and functionality.
This may explain why Cl and L35 act competitively,
whereas IHP and L35 act synergistically in decreasing Hb O2
afﬁnity. Note that spectroscopic probings by intrinsic
ﬂuorescence and UV CD show opposing effects of IHP on
the L35-induced perturbations at the a1b2 interface. This
may be explained by considering that the intrinsic ﬂuores-
cence primarily originates from b37Trp (Hirsch and Nagel,
1981), whereas the near UV CD includes the contributions of
b37Trp, a42Tyr, a140Tyr, and b145Tyr (Li et al., 2000a,b;
Perutz et al., 1974a,b,c). One possibility is that IHP binding
affects certain aromatic residues at the a1b2 interface,
contributing to the UV-CD but not to the intrinsic
ﬂuorescence where tryptophan predominates. Indeed,
b145Tyr is one of such aromatic residues. As shown for
inorganic phosphate (Safo et al., 2002), IHP may bind to the
COHbA central cavity bb cleft (b139Asn, b143His, and
b146His) and thus signiﬁcantly alter the b145Tyr as shown
in Scheme IV.
Similarly, since b93Cys hydrophobically interacts with
b145Tyr (Safo et al., 2002, PDB 1ljw), perturbation of
b145Tyr by L35 may also explain the lack of a negative
trough for the CD 280-nm region (assigned to the a1b2
interface R-state) in COHbA-AF complexes used as controls.
This is consistent with the long-range L35 effect resulting in
a greater exposure of b93Cys in COHbA-AF (Fig. 4).
In summary, it is proposed that L35 induces a transition
species characterized by the domain-speciﬁc R- and T-like
tertiary and quaternary conformations within a global
R-quaternary structure. This unifying model may clarify
the variety of structural interpretations of liganded Hb in the
presence of heterotropic allosteric effectors.
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